Werewolf Therapeutics, Inc. (NASDAQ: HOWL) has received a consensus recommendation of “Hold” from eight brokerages currently covering the firm. According to MarketBeat, one analyst rated the stock as a sell, while four recommended holding and three suggested buying shares. The average twelve-month price target from these brokerages stands at **$3.75**.
Several research analysts have recently issued reports on Werewolf Therapeutics. Notably, **HC Wainwright** revised their target price from **$10.00** to **$4.00** while maintaining a “buy” rating on December 19, 2023. On the same day, **Citizens JMP** downgraded the stock from a “strong buy” rating to a “hold.” Earlier, on November 18, **Bank of America** adjusted its price target from **$8.00** to **$7.00**, also setting a “buy” rating. **Wedbush** downgraded the shares from “outperform” to “neutral,” establishing a price target of **$1.00**. Additionally, **Weiss Ratings** reaffirmed a “sell (D-)” rating on October 8, 2023.
Institutional Investors Adjust Holdings
The trading landscape for Werewolf Therapeutics has seen adjustments from several institutional investors. **MPM Asset Management LLC** slightly increased its holdings by **0.6%** during the first quarter, now owning **4,309,860 shares** valued at approximately **$4.19 million** after acquiring an additional **25,688 shares**. Similarly, **MPM Bioimpact LLC** raised its stake by **0.9%**, owning **2,408,810 shares** worth about **$2.34 million** after adding **20,799 shares** in the last quarter.
**Bank of America Corp DE** also expanded its position by **1.2%** in the second quarter, now holding **2,129,024 shares** valued at around **$2.32 million**. **Vanguard Group Inc.** increased its holdings by **8.5%** in the third quarter, owning **1,408,047 shares** worth approximately **$2.77 million** after acquiring **109,796 shares**. Furthermore, **Jane Street Group LLC** entered the scene by purchasing a new stake worth about **$409,000** during the second quarter. Currently, approximately **64.84%** of Werewolf Therapeutics stock is held by institutional investors.
Recent Stock Performance and Earnings Report
Shares of Werewolf Therapeutics opened at **$0.64** on Monday, reflecting a **1.8%** increase. The company’s fifty-day moving average price is **$0.98**, while its two-hundred-day moving average price is **$1.27**. With a market capitalization of **$31.30 million**, Werewolf Therapeutics has a price-to-earnings ratio of **-0.40** and a beta of **0.77**. The stock has experienced a 52-week low of **$0.56** and a high of **$2.38**. It also reports a debt-to-equity ratio of **0.73**, alongside a quick ratio and current ratio of **3.87**.
On November 4, 2023, Werewolf Therapeutics released its quarterly earnings results, reporting a loss of **$0.36** per share (EPS), which exceeded analysts’ expectations of a **$0.39** loss by **$0.03**. Analysts forecast that the company will report an average EPS of **-1.56** for the current year.
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for solid tumors. Its proprietary Conditional Activation Platform aims to keep therapeutic molecules inactive in healthy tissues while activating them selectively within the tumor microenvironment. This innovation seeks to enhance anti-tumor efficacy while minimizing systemic toxicity, supporting various programs involving conditionally activated cytokine candidates and bi-specific antibody constructs.
